The story
On October 6, 2021, the World Health Organization recommended the RTS,S malaria vaccine, also called Mosquirix, for children in sub-Saharan Africa and other areas with moderate to high malaria transmission. It was the first vaccine ever approved against a human parasite, a far more complex target than a virus or a bacterium. Malaria, caused by Plasmodium parasites spread by Anopheles mosquitoes, kills about 600,000 people a year, most of them African children under five. The vaccine is given in four doses and cut cases of severe malaria by roughly 30 percent in trials, a modest result that still saves many lives at the disease's scale.
RTS,S was developed by the company GlaxoSmithKline with PATH and the Gates Foundation, starting in 1987. It uses a piece of a protein from the parasite's surface, produced with recombinant DNA technology and attached to a hepatitis B protein carrier, to train the immune system. The WHO's decision followed a pilot program that reached more than 900,000 children in Ghana, Kenya and Malawi from 2019. The disease's cause was identified in 1880, when the French army doctor Alphonse Laveran saw the parasite in a patient's blood. A second, cheaper vaccine, R21/Matrix-M from the University of Oxford, was recommended in 2023, and Cameroon began routine vaccination in 2024.
Why it mattered
- African countries began rolling out routine malaria vaccination, starting with Cameroon in January 2024.
- The R21 vaccine of Oxford and the Serum Institute of India followed, offering more doses at a lower price.
- Vaccination became a new tool alongside bed nets, insecticides and drugs in the fight against malaria.
- The success of a parasite vaccine encouraged work on vaccines for other parasitic diseases.
Sources
Drafted by AI (Claude) from the sources above and checked against them by AI; no historian has reviewed this page. Spot a mistake? Suggest a correction. How pages are made
Community notes
Loading notes…